Cisbio Bioassays and BellBrook Labs Enter into Distribution Agreement for Transcreener® EPIGEN Methyltransferase Assay

Assay provides fluorescence polarization-based detection to help advance drug research on epigenetic targets; Company's distribution network will provide researchers with access to boosted epigenetics offering

Codolet, France, and Madison, WI, USA, November 28, 2012 - Cisbio Bioassays (, global developer of products, technologies and services used for assay development and drug screening and for in vitro diagnostics, announced that it has signed a global distribution agreement with BellBrook Labs, provider of high throughput screening tools, for BellBrook Labs¹ Transcreener® EPIGEN Methyltransferase assay. Under the terms of the agreement, Cisbio Bioassays will offer this universal, fluorescence polarization-based tool for drug discovery studies in the growing field of epigenetics to pharmaceutical and biotechnology researchers in Europe, the United States and Asia through its network of sales teams.

Transcreener EPIGEN Methyltransferase is a universal detection method based on Transcreener AMP/GMP assay technology, a proprietary technology platform developed and patented by BellBrook Labs. The assay involves coupling enzymes that detect the product of methyltransferase reactions, crucial targets in epigenetic studies. Its homogeneous format enables detection at low substrate concentrations and offers researchers the sensitivity needed to detect enzyme function, as well as the technical aspects required for their industrial high throughput screening. In particular, the assay avoids difficulties in detecting specifically methylated products that are generated by methyltransferases and can be used with any kind of substrate, including complex and multi-protein.

"Cisbio Bioassays is committed to building a portfolio of specific tools for the study of epigenetic targets and, following the launch of our epigenetics toolbox in September 2012, BellBrook's Transcreener EPIGEN Methyltransferase responds to industry requests for universal assays in this important field," said François Degorce, director strategic marketing and corporate communication, Cisbio Bioassays. "By embarking on customer-oriented partnerships such as this and through our global distribution infrastructure, we can facilitate access to a more complete offering of assays and reagents for drug screening in epigenetics that help advance research in human health."

"At BellBrook, our mission is to develop technologies for researchers that accelerate their drug discovery efforts, and we can maximize their impact by leveraging select distribution partners in addition to our direct sales channel. We are excited to partner with Cisbio Bioassays in order to make our Transcreener EPIGEN technology available to a greater number of researchers involved in such a vital field of study," added Bob Lowery, CEO of BellBrook Labs.

This distribution agreement marks the second collaboration between Cisbio Bioassays and BellBrook Labs. In January 2008, Cisbio Bioassays launched HTRF® Transcreener® ADP, a universal and flexible assay for the high-throughput screening and profiling of kinases based on proprietary technologies from both companies.

About Cisbio Bioassays

Cisbio Bioassays is a global developer of products, technologies and services used in assay development and drug screening. The company pioneered the field of homogenous fluorescence methodologies via its proprietary technology, HTRF®, a highly sensitive, robust technology for the detection of molecular interactions and widely used by the pharmaceutical industry for the high throughput screening stage of drug development. Coupled with its Tag-lite® cell surface receptor investigation technology and custom assay development support, Cisbio Bioassays provides researchers with a comprehensive platform for enhanced and accelerated drug discovery. In addition, the company develops in vitro diagnostics and produces a selection of biological reagents and methods used by pharmaceutical and biotechnology companies and contract research organizations (CROs). Based in Codolet, France, with facilities in Bedford, MA, U.S.A., a laboratory in Shanghai, China and a network of distributors worldwide, Cisbio Bioassays is a business unit of the IBA group, a leading developer of technologies, pharmaceuticals and tailor-made healthcare solutions for cancer diagnosis and therapy. Please visit for more information about Cisbio Bioassays or for more information about IBA.

HTRF® is a trademark of Cisbio Bioassays.

About BellBrook Labs

BellBrook Labs is dedicated to accelerating drug discovery and biological research by providing innovative high throughput screening solutions for enzymes and phenotypic assays. The company¹s Transcreener® HTS enzyme assays, used by all of the major pharmaceutical companies, make it easy to screen thousands of different enzymes, including validated targets like kinases, as well as emerging targets like ATPases, GTPases, methyltransferases, and glycosyltransferases. The iuvo Microconduit Array technology and assay screening service is a line of unique microscale devices for miniaturization and automation of advanced cell models that are more representative of human physiology. Visit BellBrook¹s website for more information:

Transcreener® is a trademark of BellBrook Labs.


Ballou PR for Cisbio Bioassays
Christina Aplington
+33 (0)1 42 22 93 65
[email protected]
Aurélien Sohet
+33 (0) 1 42 22 99 70
[email protected]

BellBrook Labs:
Traci Pretsch
[email protected]